Aptevo Therapeutics (APVO) said Tuesday that its Mipletamig saw a 100% remission rate in group 3 of its phase 1b/2 study evaluating the drug for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.

The clinical-stage company also said no dose-limiting toxicities or cytokine release syndrome were observed in the study.

The company said it expects to present its current findings at a major medical conference in Q4.

Shares of Aptevo were up 65% in recent Tuesday premarket activity.